Business
Paysign, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results
HENDERSON, Nev., March 25, 2025--Paysign, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results
About this update from Paysign, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3029,"height":619,"url":"https://media.zenfs.com/en/business-wire.com/ec2d80217aae4235d7f1dfe9ba890a78"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DXXspRprSQXw_MqQDzc2ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ec2d80217aae4235d7f1dfe9ba890a78","width":960,"height":196},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Bg9yx8Vgvcs9zDDQsMJqqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ec2d80217aae4235d7f1dfe9ba890a78","width":1200,"height":245}},"lazy":false},{"type":"text","content":"For the Full-Year","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Full-year 2024 total revenues of $58.38 million, up 23.5% from full-year 2023","length":77,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full-year 2024 net income of $3.82 million, or diluted earnings per share of $0.07, versus net income of $6.46 million, or diluted earnings per share of $0.12 for full-year 2023","length":177,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full-year 2024 Adjusted EBITDA of $9.62 million, up 43.3% from $6.71 million a year ago, while diluted Adjusted EBITDA per share was $0.17 versus $0.12 for full-year 20231","length":171,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Total plasma center count increased by 16 during 2024, exiting the year with 480 centers, contributing to a 4.6% increase in plasma revenue versus the same period last year","length":172,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Added 33 net patient affordability programs during 2024, exiting the year with 76 active programs, leading to a 212.3% increase in pharma revenue and a 214.5% increase in pharma patient affordability revenue over the same period last year","length":238,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Exited the year with $10.77 million of unrestricted cash and zero debt while repurchasing 136,700 shares of common stock for $495 thousand","length":138,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full-year 2024 gross dollar load volume was up 4.5% over 2023","length":61,"...